2010
Leppänen,V.-M., Prota,A.E., Jeltsch,M., Anisimov,A., Kalkkinen,N., Strandin,T., Lankinen,H., Goldman,A., Ballmer-Hofer,K. and Alitalo,K. Structural determinants of growth factor binding and specificity by VEGF receptor 2. PNAS online (2010)
Dell'Era Dosch,D. and Ballmer-Hofer,K. Transmembrane domain-mediated orientation of receptor monomers in active VEGFR-2 dimers. FASEB J. 24: 32-38 (2010)
2009
Berger,P., Tersar,K., Ballmer-Hofer,K., and Suter,U. The CMT4B disease-causing proteins MTMR2 and MTMR13/SBF2 regulate AKT signaling. J Cell. Mol. Med. online (2009)
Friedli,A., Fischer,E., Novak-Hofer,I., Cohrs,S., Ballmer-Hofer,K., Schubiger,P.A., Schibli,R., and Grunberg,J. The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. Int. J. Biochem. Cell Biol. 41: 1572-1580 (2009)
Grünewald, F.S., Prota, A.E., Giese, A. and Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling.
Biochim Biophys Acta 1804: 567-580 (2010)
Stuttfeld,E. and Ballmer-Hofer,K. Structure and function of VEGF receptors. IUBMB. Life 61: 915-922 (2009)
Tremmel,M., Matzke,A., Albrecht,I., Laib,A.M., Olaku,V., Ballmer-Hofer,K., Christofori,G., Heroult,M., Augustin,H.G., Ponta,H., and Orian-Rousseau,V. A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood 114: 5236-5244 (2009)
2008
Rennel,E.S., Hamdollah-Zadeh,M.A., Wheatley,E.R., Magnussen,A., Schuler,Y., Kelly,S.P., Finucane,C., Ellison,D., Cebe-Suarez,S., Ballmer-Hofer,K., Mather,S., Stewart,L., Bates,D.O., and Harper,S.J. Recombinant human VEGF(165)b protein is an effective anti-cancer agent in mice. Eur. J. Cancer 44 (13):1883-94 (2008)
Kawamura,H., Li,X., Goishi,K., van Meeteren,L.A., Jakobsson,L., Cebe-Suarez,S., Shimizu,A., Edholm,D., Ballmer-Hofer,K., Kjellen,L., Klagsbrun,M., and Claesson-Welsh,L. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 112:3638-49 (2008)
Cébe-Suarez,S., Grunewald,F.S., Jaussi,R., Li,X., Claesson-Welsh,L., Spillmann,D., Mercer,A.A., Prota,A.E., and Ballmer-Hofer,K. Orf virus VEGF-E NZ2 promotes paracellular NRP-1/VEGFR-2 coreceptor assembly via the peptide RPPR. FASEB J. 22: 3078-3086 (2008)
Soro,S., Orecchia,A., Morbidelli,L., Lacal,P.M., Morea,V., Ballmer-Hofer,K., Ruffini,F., Ziche,M., D'Atri,S., Zambruno,G., Tramontano,A., and Failla,C.M. A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through {alpha}5{beta}1 integrin. Blood 111: 3479-3488 (2008)
2007
Zehnder-Fjällman, A.H.M., Marty, C., Halin, C., Hohn, A., Schibli, R., Ballmer-Hofer, K., and Schwendener, R.A. Evaluation of anti-VEGFR-3 specific scFv antibodies as potential therapeutic and diagnostic tools for tumor lymph-angiogenesis Oncology Reports 18: 933-941 (2007)
Ruch,C., Skiniotis,G., Steinmetz,M.O., Walz,T., andBallmer-Hofer,K. Structure of a VEGF / VEGF-receptor complex
as determined by EM. Nature Structural & Molecular Biology 14: 249-250 (2007)
2006
Wagner,A., Pieren,M., Schulze-Briese,C., Ballmer-Hofer,K., and Prota,A.E. Structure determination of VEGF-E by sulfur SAD. Acta Crystallogr. D. Biol. Crystallogr. 62: 1430-1434 (2006)
Cébe-Suarez,S., Pieren,M., Cariolato,L., Arn,S., Hoffmann,U., Bogucki,A., Manlius,C., Wood, J., Ballmer-Hofer,K. A (2006) VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2, Cellular and Molecular Life Sciences (CMLS) 63: 2067-2077 (2006)
Cébe-Suarez,S., Zehnder-Fjallman,A., and Ballmer-Hofer,K. The role of VEGF receptors in angiogenesis; complex partnerships. Cellular and Molecular Life Sciences (CMLS) 63: 601-615 (2006)
Marty,C., Langer-Machova,Z., Sigrist,S., Schott,H., Schwendener,R.A., and Ballmer-Hofer,K. Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Cancer Lett. 235: 298-308 (2006)
Pieren,M., Prota,A., Ruch,C., Kostrewa,D., Wagner,A., Biedermann,K., Winkler,F., and Ballmer-Hofer,K. Crystal structure of the Orf virus NZ2 variant of VEGF-E: Implications for receptor specificity. J. Biol. Chem. 281: 19578-19587 (2006)
Zeisberger,S.M., Odermatt,B., Marty,C., Zehnder-Fjallman,A.H., Ballmer-Hofer,K., and Schwendener,R.A. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer. 95: 272-281 (2006)
2005
Marty,C. and Schwendener,R.A. Cytotoxic Tumor Targeting With scFv Antibody-Modified Liposomes. Methods Mol. Med. 109: 389-402 (2005)
Rubio Demirovic, A., Marty, C., Console, S., Zeisberger, S.M., Ruch, C., Jaussi, R., Schwendener, R.A., and Ballmer-Hofer, K. Targeting human cancer cells with VEGF Receptor-2-directed liposomes. Oncol Rep. 13(2): 319-24 (2005)
Zaric,B., Chami,M., Remigy,H., Engel,A., Ballmer-Hofer,K., Winkler,F.K., and Kambach,C. Reconstitution of two recombinant LSM protein complexes reveals aspects of their architecture, assembly and function. J. Biol. Chem. 280: 16066-16075 (2005)
Marty,C., Langer-Machova,Z., Sigrist,S., Schott,H., Schwendener,R.A., and Ballmer-Hofer,K. Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Cancer Lett. 235: 298-308 (2005)
2004
Storni,T., Ruedl,C., Schwarz,K., Schwendener,R.A., Renner,W.A., and Bachmann,M.F. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol. 172: 1777-1785 (2004)
Schwendener, R.A., Schott, H. Lipophilic Arabinofuranosyl Cytosine Derivatives in Liposomes. Methods in Enzymology 373 (2004)
Wergin,M.C., Ballmer-Hofer,K., Roos,M., Achermann,R.E., Inteeworn,N., Akens,M.K., Blattmann,H., and Kaser-Hotz,B. Preliminary study of plasma vascular endothelial growth factor (VEGF) during low- and high-dose radiation therapy of dogs with spontaneous tumors. Vet. Radiol. Ultrasound 45: 247-254 (2004)
Marty,C., Meylan,C., Schott,H., Ballmer-Hofer,K., and Schwendener,R.A. Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell Mol. Life Sci. 61: 1785-1794 (2004)
Engler,O.B., Schwendener,R.A., Dai,W.J., Wolk,B., Pichler,W., Moradpour,D., Brunner,T., and Cerny,A. A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins.Vaccine 23: 58-68 (2004)
older
Aichele,P., Zinke,J., Grode,L., Schwendener,R.A., Kaufmann,S.H., and Seiler,P. Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses. J. Immunol. 171: 1148-1155 (2003)
Autiero, M., Waltenberger, J., Communi, D., Kranz, A., Moons, L., Lambrechts, D., Kroll, J., Plaisance, S., De Mol, M., Bono, F., Kliche, S., Fellbrich, G., Ballmer-Hofer, K., Maglione, D., Mayr-Beyrle, U., Dewerchin, M., Dombrowski, S., Stanimovic, D., Van Hummelen, P., Dehio, C., Hicklin, D., Persico, G., Herbert, J.-M., Communi, D., Shibuya, M., Collen, D., Conway, E.M., and Carmeliet, P. Role of PlGF in intra- and intermolecular crosstalk between VEGF receptors Flk1 and Flt1. Nature Med. 9: 936-943 (2003)
Rubio Demirovic, A., Canadi, J., Weiglhofer, W., Scheidegger, P., Jaussi, R. and Ballmer-Hofer, K. HIV TAT-derived Basic Peptide Interacts with Ig-like Domain 3 of VEGF Receptor 2. Biol. Chem. 384: 1435-1441 (2003)
Madjdpour,C., Jewell,U.R., Kneller,S., Ziegler,U., Schwendener,R., Booy,C., Klausli,L., Pasch,T., Schimmer,R.C., and Beck-Schimmer,B. Decreased alveolar oxygen induces lung inflammation. Am. J. Physiol Lung Cell Mol. Physiol 284: L360-L367 (2003)
Console, S., Marty, C., García-Echeverría, C., Schwendener, R. and Ballmer-Hofer K. Antennapedia and HIV TAT ‘protein transduction domains' promote endocytosis of high Mr cargo upon binding to cell surface glycosaminoglycans. J. Biol. Chem. 278: 35109-35114 (2003)
Seiler,P., Schwendener,R.A., Bandermann,S., Brinkmann,V., Grode,L., Kaufmann,S.H., and Aichele,P. Limited mycobacterial infection of the liver as a consequence of its microanatomical structure causing restriction of mycobacterial growth to professional phagocytes. Infect. Immun. 69: 7922-7926 (2001)
Marty, C., Odermatt, B., Ballmer-Hofer, K., Schott, H., Neri, D., Klemenz; R., and Schwendener, R.A. Inhibition of Tumor Growth by Specific Targeting of anti-ED-B Fibronectin scFv Antibody modified LiposomesImmunoliposomes specific to Angiogenesis to murine F9 Teratocarcinoma Tumors. British J. Cancer 87: 106-112 (2002)
Bueno Da Costa,M.H., Quintilio,W., Tanizaki,M.M., Sant'Anna,O.A., Schwendener,R.A., and de Araujo,P.S. Heat shock protein micro-encapsulation as a double tool for the improvement of new generation vaccines. J. Liposome Res. 12: 29-3 (2002)
Scheidegger, P., Weiglhofer, W., Suarez, S., Console, S., Waltenberger, J., Pepper, M., Jaussi, R., and Ballmer-Hofer, K.
Signalling properties of a human immunodeficiency virus-encoded angiogenic peptide mimicking vascular endothelial growth factor activity. Biochem. J. 353: 569-578 (2001)
Marty, C., Scheidegger, P., Ballmer-Hofer, K., Klemenz, R. and Schwendener, R.A.
Production of functionalized single-chain Fv antibody fragments binding to the EDB domain of the B-isoform of fibronectin in Pichia Pastoris. Protein Expression and Purification 21: 156-164 (2001)
Suarez, S., Ballmer-Hofer, K.
VEGF transiently disrupts gap junctional communication in endothelial cells. J. Cell. Sci. 114: 1229-1235 (2001)
Scheidegger, P., Weiglhofer, W., Suarez, S., Kaser-Hotz, B., Steiner, R., Ballmer-Hofer, K. and Jaussi, R.
Vascular endothelial growth factor (VEGF) and its receptors in tumor-bearing dogs. Biol. Chemistry 380: 1449-1454 (1999)
